Search Results for: FLT1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel FLT3 fms related receptor tyrosine kinase 3
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • FLT3 Signaling
  • FLT3 Signaling
  • STAT5 Activation
  • FLT3 mutants bind TKIs
  • STAT5 activation downstream of FLT3 ITD mutants
  • KW2449-resistant FLT3 mutants
  • semaxanib-resistant FLT3 mutants
  • crenolanib-resistant FLT3 mutants
  • gilteritinib-resistant FLT3 mutants
  • lestaurtinib-resistant FLT3 mutants
  • midostaurin-resistant FLT3 mutants
  • pexidartinib-resistant FLT3 mutants
  • ponatinib-resistant FLT3 mutants
  • quizartinib-resistant FLT3 mutants
  • sorafenib-resistant FLT3 mutants
  • sunitinib-resistant FLT3 mutants
  • tandutinib-resistant FLT3 mutants
  • linifanib-resistant FLT3 mutants
  • tamatinib-resistant FLT3 mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Negative regulation of FLT3
  • FLT3 signaling through SRC family kinases
  • FLT3 signaling through SRC family kinases
  • FLT3 signaling by CBL mutants
  • Sorafenib
  • Sunitinib
  • XL999
  • Tandutinib
  • ABT-869
  • Lestaurtinib
  • Midostaurin
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Gilteritinib
  • Brigatinib
  • Fedratinib
  • Amuvatinib
  • Quizartinib
  • Pexidartinib
  • Pralsetinib
  • Acute myeloid leukemia (AML)
Novel ALOX5AP arachidonate 5-lipoxygenase activating protein
  • Synthesis of 5-eicosatetraenoic acids
  • Synthesis of Leukotrienes (LT) and Eoxins (EX)
  • Synthesis of Lipoxins (LX)
  • DG031
  • AM103
  • Fiboflapon
Novel ARL2BP ADP ribosylation factor like GTPase 2 binding protein
  • Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane
Novel CDK8 cyclin dependent kinase 8
  • PPARA activates gene expression
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Generic Transcription Pathway
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • Alvocidib
Novel HMGB1 high mobility group box 1
  • Apoptosis induced DNA fragmentation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TLR by endogenous ligand
  • Neutrophil degranulation
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • TRAF6 mediated NF-kB activation
  • Chloroquine
  • Ethyl pyruvate
Novel LATS2 large tumor suppressor kinase 2
  • Signaling by Hippo
Novel MIPEP mitochondrial intermediate peptidase
Novel RASSF9 Ras association domain family member 9
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Urea
  • Gastric cancer
  • Colorectal cancer
  • Endometrial Cancer
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Thyroid cancer
  • Hepatocellular carcinoma
ATR ATR serine/threonine kinase
  • Meiotic synapsis
  • Activation of ATR in response to replication stress
  • Regulation of HSF1-mediated heat shock response
  • HDR through Single Strand Annealing (SSA)
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Fanconi Anemia Pathway
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Alveolar rhabdomyosarcoma
  • Seckel syndrome
PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Costimulation by the CD28 family
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • FLT3 Signaling
  • STAT5 Activation
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Dodecyltrimethylammonium
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Metachondromatosis
STAT1 signal transducer and activator of transcription 1
  • Interleukin-6 signaling
  • ISG15 antiviral mechanism
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Regulation of RUNX2 expression and activity
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
  • IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency
STAT3 signal transducer and activator of transcription 3
  • Interleukin-6 signaling
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Signalling to STAT3
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by Leptin
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Association of TriC/CCT with target proteins during biosynthesis
  • Transcriptional regulation of pluripotent stem cells
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Activates STAT3
  • PTK6 Activates STAT3
  • Interleukin-20 family signaling
  • MET activates STAT3
  • MET activates STAT3
  • Interleukin-15 signaling
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • Interleukin-37 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Transcriptional regulation of granulopoiesis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • ENMD-1198
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
  • Oral cancer
VEGFA vascular endothelial growth factor A
  • Platelet degranulation
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by VEGF
  • VEGF ligand-receptor interactions
  • VEGF binds to VEGFR leading to receptor dimerization
  • Interleukin-4 and Interleukin-13 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Bevacizumab
  • Minocycline
  • Gliclazide
  • Carvedilol
  • Ranibizumab
  • Pidolic acid
  • Pegaptanib
  • Vandetanib
  • ABT-510
  • Veglin
  • Denibulin
  • SNS-032
  • Bevasiranib
  • Dalteparin
  • Aflibercept
  • Chondroitin sulfate
  • Foreskin keratinocyte (neonatal)
  • Brolucizumab
  • Faricimab
  • Gastric cancer
VEGFB vascular endothelial growth factor B
  • Platelet degranulation
  • VEGF ligand-receptor interactions
  • VEGF binds to VEGFR leading to receptor dimerization
  • Aflibercept
  • Gastric cancer
CRK CRK proto-oncogene, adaptor protein
  • ARMS-mediated activation
  • ARMS-mediated activation
  • Downstream signal transduction
  • Regulation of actin dynamics for phagocytic cup formation
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Triglyme
  • Fostamatinib
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
KDR kinase insert domain receptor
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Integrin cell surface interactions
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • Sorafenib
  • Sunitinib
  • 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
  • Cediranib
  • Vatalanib
  • XL999
  • TG-100801
  • XL820
  • CYC116
  • Ramucirumab
  • Pegdinetanib
  • RAF-265
  • ABT-869
  • IMC-1C11
  • Semaxanib
  • Pazopanib
  • Midostaurin
  • Axitinib
  • 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
  • N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
  • N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
  • 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
  • N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
  • N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
  • 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
  • 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
  • N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
  • N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Fostamatinib
  • Erdafitinib
  • Foretinib
  • Ripretinib
  • Pralsetinib
NCK1 NCK adaptor protein 1
  • Downstream signal transduction
  • Generation of second messenger molecules
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • Nephrin family interactions
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Activation of RAC1
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers

Page 1 out of 2 pages